[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"guillain-barre-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:guillain-barre-syndrome":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,46,72,95,122,145],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100594543","phase-3-an-open-label-clinical-study-to-evaluate-tanruprubart-also-commonly-known-as-anx005-in-participants-with-guillain-barr-syndrome-forward-study-100594543",false,"NCT07020819","An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study)","An Open-Label Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of a Single Dose of Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (GBS) (FORWARD Study)","Key Inclusion Criteria:\n\n* Diagnosis of GBS according to the National Institute of Neurological Disorders and Stroke Diagnostic Criteria for GBS.\n* Onset of GBS-related weakness ≤10 days before start of infusion on Day 1\n* GBS-disability score (DS) score of 3, 4, or 5 at screening and before start of infusion on Day 1.\n\nKey Exclusion Criteria:\n\n* Previous or intended treatment with either plasma exchange or IV immunoglobulin for GBS.\n* Diagnosis of a variant of GBS, including Miller Fisher syndrome, Bickerstaff's encephalitis, and overlap syndromes.\n\nOther protocol-defined criteria may apply.","ALL","12 Years","85 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","The goal of this open label study is to measure pharmacokinetics, pharmacodynamics, early efficacy, and safety of tanruprubart in adult and pediatric participants, in the United States, Canada, and Europe.",[27],"Guillain-Barre Syndrome",[27,29,30,31,32],"GBS","ANX005","Tanruprubart","FORWARD study","RECRUITING","2026-05-27",{"date":36,"type":37},"2026-05-28","ACTUAL",{"date":39,"type":37},"2025-09-12",{"date":41,"type":21},"2028-06-30",{"name":43,"class":44},"Annexon, Inc.","INDUSTRY",13,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":60,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":71},"100592675","noninvasive-support-for-acute-respiratory-failure-in-guillain-barr-syndrome-100592675","NCT06996509","Noninvasive Support for Acute Respiratory Failure in Guillain-Barré Syndrome","Prospective, Randomized, Controlled, Open-Label Single-Center Trial Comparing High-Velocity Nasal Insufflation (HVNI) Versus Non-Invasive Ventilation (NIV) for Acute Respiratory Failure in Guillain-Barré Syndrome","Inclusion Criteria:\n\n* Age ≥ 18 years\n* GBS per Brighton criteria (clinical ± cerebrospinal fluid (CSF)\u002Felectrodiagnostics)\n* Moderate acute respiratory failure (vital capacity (VC) 15-20 mL\u002Fkg and\u002For arterial partial pressure of carbon dioxide (PaCO₂) \\> 45 mmHg or arterial partial pressure of oxygen (PaO₂) \\\u003C 70 mmHg on room air (RA) and\u002For respiratory rate (RR) \\> 24 \u002Fmin)\n* Hughes Grade 3-4, The Erasmus Guillain-Barré Syndrome Respiratory Insufficiency Score (EGRIS) 1-3, Medical Research Council (MRC) sum score 20-40\n* Glasgow Coma Scale (GCS) ≥ 13, intact cough\u002Fgag, stable hemodynamics\n* Onset of respiratory symptoms ≤ 7 days\n\nExclusion Criteria:\n\n* Chronic respiratory disease (COPD, interstitial lung diseases (ILD), persistent asthma)\n* Immediate need for invasive ventilation (VC \\\u003C 10 mL\u002Fkg, unresponsive severe gas-exchange derangement)\n* Severe bulbar dysfunction or prior intubation for the current illness\n* Contraindications to HVNC\u002FNIV (facial trauma, untreated pneumothorax, agitation, vomiting)\n* Pregnancy\n* Severe comorbidity limiting prognosis.\n* Declined consent","18 Years",{"count":55,"type":21},80,[57],"NA","This study will involve 70 adult patients with Guillain-Barré syndrome who have severe breathing problems. It will compare two types of breathing support: high-velocity nasal cannula (HVNC) (which delivers heated and humidified air at 35-60 L\u002Fmin) and bi-level noninvasive ventilation (NIV) (which uses two pressure levels: inspiratory positive airway pressure (IPAP) 10-16 cmH₂O and expiratory positive airway pressure (EPAP) 5-8O). The main goal is to see how many patients can stop using non-invasive support without needing a breathing machine by Day 30. Other goals include how long it takes to stop using support, how comfortable patients feel, how long they stay in the ICU or hospital, how many days they can breathe on their own, and the number of deaths in 30 days. The main goal is to see how many patients can stop using non-invasive support without needing invasive ventilation by Day 30, while also looking at other factors like how long it takes to stop assistance, how comfortable patients are, how long they stay in the hospital, how many days they can breathe on their own, the number of deaths within 30 days, and their overall health.",[27],[29],"2026-04-26",{"date":63,"type":37},"2026-04-30",{"date":65,"type":37},"2025-08-01",{"date":67,"type":21},"2026-11-01",{"name":69,"class":70},"Assiut University","OTHER",2,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":80,"phases":4,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":94},"100563136","early-vs-late-tracheostomy-in-patients-with-guillain--barre-syndrome-100563136","NCT06612242","Early vs. Late Tracheostomy in Patients With Guillain -Barre Syndrome","Early vs. Late Tracheostomy in Patients With Guillain -Barre Syndrome: Comparison of Clinical Outcomes- a Retrospective Study","Inclusion Criteria: All patients aged 18--99 who were admitted to the general intensive care unit from January 2012 to September 2024 with a diagnosis of Guillain-Barre syndrome who required mechanical ventilation and underwent tracheostomy during ICU stay.\n\n\\-\n\nExclusion Criteria: Missing recoreded data\n\n\\-",{"count":20,"type":21},"OBSERVATIONAL","Tracheostomy is one of the most common procedures in the intensive care unit in patients who need prolonged invasive mechanical ventilation. There is controversy in the literature regarding the ideal timing for performing tracheostomy in critically ill patients. Early tracheostomy may be associated with a decrease in ventilation days and hospitalization. We would like to investigate whether in ventilated patients with Guillain Barre syndrome, early tracheostomy will be associated with decreased ventilation days, decreased mortality and shorter hospital and ICU length of stay.",[83,84],"Guillain Barre Syndrome","Mechanical Ventilation","2025-05-07",{"date":87,"type":37},"2025-05-13",{"date":89,"type":37},"2025-02-01",{"date":91,"type":21},"2027-01-01",{"name":93,"class":70},"Meir Medical Center",1,{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":103,"enrollmentInfo":104,"targetDuration":4,"studyType":22,"phases":106,"briefSummary":107,"conditions":108,"keywords":109,"overallStatus":112,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":94},"100448091","comparison-of-the-efficacy-and-safety-of-immunoadsorption-and-intravenous-immunoglobulin-for-guillain-barre-syndrome-100448091","NCT05114941","Comparison of the Efficacy and Safety of Immunoadsorption and Intravenous Immunoglobulin for Guillain-Barre Syndrome","A Prospective, Multi-center, Randomized Parallel Controlled Clinical Study on the Efficacy and Safety of Protein A Immunoadsorption and Intravenous Immunoglobulin in the Treatment of Guillain-Barre Syndrome","GBS-PRAISING","Inclusion Criteria:\n\n1. Meet the diagnostic criteria of Guillain - Barre syndrome;\n2. The onset is within 2 weeks;\n3. Age is greater than or equal to 18 years old and less than or equal to 60 years old;\n4. Hughes function classification is greater than or equal to 3;\n5. The subject or his legal representative can understand the purpose of the research, show sufficient compliance with the research protocol, and sign an informed consent form.\n\nExclusion Criteria:\n\n1. Those who are pregnant;\n2. Three months before the screening period, receive immunoadsorption therapy or intravenous immunoglobulin therapy;\n3. Those who have a history of allergies in the membrane of the plasma separator;\n4. Those who must use angiotensin-converting enzyme inhibitor drugs within 1 week before being included in the trial and during treatment and cannot be stopped;\n5. Severe active bleeding or diffuse intravascular coagulation, patients with systemic circulatory failure that are difficult to correct with drugs;\n6. Severe cardiac insufficiency, that is, those who have reached NYHA IV according to the heart failure classification standards of the New York Heart Association (NYHA);\n7. There are contraindications to intravenous immunoglobulin;\n8. Those with other system autoimmune diseases;\n9. Diagnosis of variant GBS: such as Miller-Fisher syndrome, GBS with cranial nerve damage, sensory GBS, pan-autonomous GBS. Patients with chronic inflammatory demyelinating polyperipheral neuropathy whose condition has been significantly alleviated when visiting a doctor;\n10. Subjects who have participated in any other drug or medical device clinical trials within 1 month before entering the screening period; Note: Subjects who participated in observational studies (that is, the study does not require changes or other interventions) will not be excluded;\n11. Patients who cannot obtain informed consent;\n12. Those who cannot receive active and comprehensive treatment.","60 Years",{"count":105,"type":21},204,[57],"Guillain-Barre syndrome is an immune-mediated acute inflammatory peripheral neuropathy. The currently effective treatment methods include intravenous immunoglobulin and plasma exchange. Immunoadsorption has been widely used to treat immune-related diseases. There are currently no prospective large-sample clinical trials of immunoadsorption therapy for Guillain-Barre syndrome. The neuro-intensive care unit of the First Affiliated Hospital of Zhengzhou University is preparing to carry out a prospective, multi-center, randomized parallel controlled clinical study on the efficacy and safety of protein A immunoadsorption and intravenous immunoglobulin (IVIG) in the treatment of Guillain-Barre syndrome. It is estimated that 204 patients with Guillain-Barre syndrome will be included. The patients will be randomly assigned to the immunoadsorption group and the IVIG group. The primary outcome measure: changes in Hughes scores (4 weeks after starting treatment vs. baseline (before starting treatment) ). This study aims to explore the efficacy and safety of protein A immunoadsorption and intravenous immunoglobulin in the treatment of Guillain-Barre syndrome.",[27],[110,111],"immunoadsorption","intravenous immunoglobulin","NOT_YET_RECRUITING","2025-03-10",{"date":115,"type":37},"2025-03-12",{"date":117,"type":21},"2026-01-01",{"date":119,"type":21},"2026-12-31",{"name":121,"class":70},"The First Affiliated Hospital of Zhengzhou University",{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":4,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":16,"minAge":129,"maxAge":130,"enrollmentInfo":131,"targetDuration":4,"studyType":22,"phases":133,"briefSummary":134,"conditions":135,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":94},"100528935","ventilator-trigger-sensitivity-adjustment-versus-threshold-inspiratory-muscle-training-on-arterial-blood-gases-100528935","NCT06167239","Ventilator Trigger Sensitivity Adjustment Versus Threshold Inspiratory Muscle Training on Arterial Blood Gases","Effect of Ventilator Trigger Sensitivity Adjustment Versus Threshold Inspiratory Muscle Training on Arterial Blood Gases in Mechanically Ventilated Patients, a Randomized Clinical Trail","Inclusion Criteria:\n\n1. Difficult to wean Guillain barre patients who have been on MV for at least 48 hours. Difficult to wean subjects have been defined as those who fail the first spontaneous breathing trial (SBT)and may require up to 3 SBTs or up to 7 d from the first attempt to achieve successful weaning (B´eduneau G. et al.,2017) and (Annia F. et al.,2019).\n2. Age: \\>18 years.\n3. Both sexes will be included.\n4. Ventilator mode: Pressure support mode with FiO2≤ 0.5, positive end expiratory pressure (PEEP) will be\\\u003C8-10cm\u002FH2Oand respiratory rate \\\u003C 25.\n5. Conscious oriented patient with Glasgow coma score ≥13.\n6. Alertness will be titrated to a Riker Sedation Agitation Score of 4.\n7. PH\\>7.25, arterial oxygen saturation \\>90%.\n8. Cardiovascular stability.\n9. Maximal inspiratory pressure from 15 to 30 cm H2O and able to trigger spontaneous breaths on ventilator.\n\nExclusion Criteria:\n\n1. Persistent hemodynamic instability as life threatening arrhythmias, acute heart failure.\n2. Severe breathlessness, when spontaneously breathing.\n3. Any progressive neuromuscular disease that would interfere with responding to inspiratory muscle training (non-stationary course).\n4. Spinal cord injury.\n5. Skeletal pathology (scoliosis, flail chest, spinal instrumentation) that would seriously impair the movement of the chest wall and ribs.\n6. Patients on heavy sedation and respiratory muscle paralysis.\n7. High peak airway pressure (barotraumas).\n8. BMI ≥ 40.","20 Years","55 Years",{"count":132,"type":21},45,[57],"The aim of the current study is to compare the effect of ventilator trigger sensitivity adjustment versus threshold inspiratory muscle training on arterial blood gases in mechanically ventilated patients.",[27],"2024-12-16",{"date":138,"type":37},"2024-12-17",{"date":140,"type":37},"2023-05-02",{"date":142,"type":21},"2024-12",{"name":144,"class":70},"Cairo University",{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":4,"eligibilityCriteria":151,"healthyVolunteers":152,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":153,"targetDuration":4,"studyType":80,"phases":4,"briefSummary":155,"conditions":156,"keywords":167,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":94},"100554663","biomarkers-in-autoimmune-disease-of-nervous-system-100554663","NCT06502015","Biomarkers in Autoimmune Disease of Nervous System","Biomarkers of Neurological Autoimmune Diseases","Inclusion Criteria:\n\n* Clinical diagnosis with autoinflammatory diseases of the nervous system, including: Neuromyelitis Optica Spectrum Disorder (NMOSD), Myasthenia Gravis (MG), Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), idiopathic inflammatory myopathy(IIM), multiple sclerosis (MS), autoimmune encephalitis (AE), Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD), ect al.\n* sex and age-matched healthy individuals\n\nExclusion Criteria:\n\n* Known history of primary immunodeficiency (innate or acquired).\n* Patients with severe central nervous system, pulmonary, or other systemic infections.\n* Patients with secondary central nervous system demyelinating lesions, such as those caused by vasculitis, systemic lupus erythematosus, and Sjögren's syndrome.\n* Patients with vascular (including hemorrhagic and ischemic), hereditary metabolic, neoplastic, or toxic diseases.\n* Pregnant or lactating women.",true,{"count":154,"type":21},50000,"Neurological autoimmune diseases are a group of disorders characterized by the abnormal immune response attacking the nervous system, including the brain, spinal cord and peripheral nerves. These diseases exhibit high heterogeneity, diverse clinical presentations, and are challenging to diagnose and manage due to a lack of effective treatments. In this study, the investigators will recruit eight kinds of autoimmune diseases of nervous system including Neuromyelitis Optica Spectrum Disorder (NMOSD), Myasthenia Gravis (MG), Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), idiopathic inflammatory myopathy (IIM), and multiple sclerosis (MS), autoimmune encephalitis (AE), Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD). Through this study, the investigators aim to discover biomarkers with high sensitivity, specificity, and stability, which can support early diagnosis, disease monitoring, and personalized treatment for neurological autoimmune diseases, thereby improving the quality of life and prognosis for patients.",[157,158,159,27,160,161,162,163,164,165,166],"Autoimmune Diseases of the Nervous System","Neuromyelitis Optica Spectrum Disorder","Multiple Sclerosis","Acute Disseminated Encephalomyelitis","Autoimmune Encephalitis","Stiff-Person Syndrome","Myasthenia Gravis","Chronic Inflammatory Demyelinating Polyradiculoneuropathy","Idiopathic Inflammatory Myopathies","Autoimmune Diseases",[168,157,169],"Biomarker","Immune cell","2024-11-17",{"date":172,"type":37},"2024-11-20",{"date":174,"type":37},"2024-07-31",{"date":176,"type":21},"2027-07",{"name":178,"class":70},"Tongji Hospital"]